

Edgar Filing: ACAMBIS PLC - Form 6-K

ACAMBIS PLC
Form 6-K
March 01, 2007

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Report of Foreign Private Issuer

Pursuant to Rule 13s - 16 or 15d - 16 of
the Securities Exchange Act of 1934

For the month of February 2007

Acambis plc
(Translation of registrant's name into English)

Peterhouse Technology Park
100 Fulbourn Road
Cambridge CB1 9PT
England

(address of principal executive offices)

(Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F)

Forms 20-F ☒ Form 40-F ☐

Indicate by check mark whether the registrant by furnishing the information
contained in this Form also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934).

Yes ☐ No ☒

(if "Yes" is marked, indicate below the file number assigned to the registrant
in connection with Rule 12g3-2(b): 82-).

Enclosure:

1 Holding(s) in Company dated 01 February 2007
2 Holding(s) in Company dated 08 February 2007
3 Holding(s) in Company dated 13 February 2007
4 Holding(s) in Company dated 16 February 2007
5 Holding(s) in Company dated 19 February 2007
6 Holding(s) in Company dated 23 February 2007
7 Notice of Results dated 28 February 2007
8 Phase 3 efficacy data dated 1 March 2007

Enclosure 1

Edgar Filing: ACAMBIS PLC - Form 6-K

SCHEDULE 10 NOTIFICATION OF MAJOR INTERESTS IN SHARES

1. Name of company

Acambis plc

2. Name of shareholder having a major interest

Legal & General Group plc

3. Please state whether notification indicates that it is in respect of holding of the shareholder named in 2 above or in respect of a non-beneficial interest or in the case of an individual holder if it is a holding of that person's spouse or children under the age of 18

As above

4. Name of the registered holder(s) and, if more than one holder, the number of shares held by each of them

Legal & General Group Plc (Direct and Indirect) (Group)
7,315,855-6.79% = Total Position)

Legal & General Investment Management (Holdings) Limited
(LGIMH) (Direct and Indirect) (7,315,855-6.79%)

Legal & General Investment Management Limited (Indirect)
(LGIM) (7,315,855 - 6.79% = Total Position)

Legal & General Group Plc (Direct) (L&G) (6,393,925-5.93% = LGAS, LGPL & PMC)

Legal & General Investment
Management (Holdings) Limited
(Direct) (LGIMHD) (3,342,882-3.10%
= PMC)

Legal & General Insurance
Holdings Limited (Direct)

Legal & General Assurance
(Pensions Management) Limited
(PMC) (3,342,882-3.10%)

Legal & General Assurance Society Limited
(LGAS & LGPL)

Legal & General
Pensions Limited (Direct) (LPGL)

5. Number of shares / amount of stock acquired

Not disclosed

6. Percentage of issued class

Not disclosed

7. Number of shares / amount of stock disposed

N/A

8. Percentage of issued class

N/A

9. Class of security

Edgar Filing: ACAMBIS PLC - Form 6-K

Ordinary shares of 10p each

10. Date of transaction

Not disclosed

11. Date company informed

31 January 2007

12. Total holding following this notification

7,315,855 shares

13. Total percentage holding of issued class following this notification

6.79%

14. Any additional information

N/a

5. Name of contact and telephone number for queries

Elizabeth Brown, Company Secretary

+44 (0) 1223 275 300

16. Name and signature of authorised company official responsible for making this notification

Elizabeth Brown

Date of notification

1 February 2007

The FSA does not give any express or implied warranty as to the accuracy of this document or material and does not accept any liability for error or omission. The FSA is not liable for any damages (including, without limitation, damages for loss of business or loss of profits) arising in contract, tort or otherwise from the use of or inability to use this document, or any material contained in it, or from any action or decision taken as a result of using this document or any such material.

Enclosure 2

Holding in Company

Cambridge, UK and Cambridge, Massachusetts - 8 February 2007 - Acambis plc ("Acambis") (LSE: ACM) announces an interest in its shares by The Goldman Sachs Group, Inc.

On 7 February 2007, Acambis received notification that, as of the close of business on 31 January 2007, The Goldman Sachs Group, Inc., ("GS Inc") of 85

Edgar Filing: ACAMBIS PLC - Form 6-K

Broad Street, New York, NY 10004, USA, was interested in a total of 16,225,116 ordinary shares of 10p each, representing a 15.07% holding of Acambis' issued share capital.

Of these 16,225,116 shares:

- a) The interest in 14,738,501 shares arose from a beneficial interest held by Goldman Sachs International, a wholly-owned indirect subsidiary of GS Inc. These shares are, or will be, registered at CREST in account CREPTMP; and
- b) The interest in 1,126,115 shares arose from an interest held by Goldman, Sachs & Co., a wholly-owned direct subsidiary of GS Inc, acting as custodian for its customers. These shares are, or will be, registered in the name of Goldman Sachs Securities (Nominees), Limited; and
- c) The interest in 360,500 shares arose from an interest held by GS&Co, acting as custodian of 180,250 ADRs; these ADRs are, or will be, held at The Depositary Trust Company, New York.

-ends-

Enquiries:

Acambis plc

Elizabeth Brown, Company Secretary: Tel: +44 (0) 1223 275 300
Lyndsay Wright, VP, Communications and Investor Relations: Tel: +44 (0) 1223 275 300

About Acambis

Acambis is a leading biotechnology company targeting infectious diseases with novel vaccines. Acambis' development-stage pipeline includes vaccines that could either offer improvements over existing products or target unmet medical needs. As well as ChimeriVax-JE, Acambis' proprietary ChimeriVax technology, developed in association with St Louis University, has also been used to develop ChimeriVax-West Nile, which is undergoing Phase 2 clinical testing, making it the most advanced investigational vaccine against the West Nile virus. Acambis also has the only vaccine in development against Clostridium difficile bacteria, a leading cause of hospital-acquired infections. Recognised internationally as the leading producer of smallpox vaccines, Acambis is developing an investigational smallpox vaccine, ACAM2000, and is manufacturing emergency-use stockpiles of this investigational vaccine for the US Government and other governments around the world.

Acambis is based in Cambridge, UK and Cambridge, Massachusetts, US, and is listed on the London Stock Exchange (ACM). More information is available at www.acambis.com.

"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995:

The statements in this news release that are not historical facts are forward-looking statements that involve risks and uncertainties, including the timing and results of clinical trials, product development, manufacturing and commercialisation risks, the risks of satisfying the regulatory approval process

Edgar Filing: ACAMBIS PLC - Form 6-K

in a timely manner, the need for and the availability of additional capital. For a discussion of these and other risks and uncertainties see "Risk management" in the Company's 2005 Annual Report and "Risk factors" in its Form 20-F, in addition to those detailed on the Company's website and in the Company's filings made with the Securities and Exchange Commission from time to time. These forward-looking statements are based on estimates and assumptions made by the management of Acambis and are believed to be reasonable, though are inherently uncertain and difficult to predict. Actual results or experience could differ materially from the forward-looking statements.

Enclosure 3

Holding in Company

Cambridge, UK and Cambridge, Massachusetts - 13 February 2007 - Acambis plc ("Acambis") (LSE: ACM) announces an interest in its shares by The Goldman Sachs Group, Inc.

On 12 February 2007, Acambis received notification that, as of the close of business on 8 February 2007, The Goldman Sachs Group, Inc., ("GS Inc") of 85 Broad Street, New York, NY 10004, USA, was interested in a total of 15,724,759 ordinary shares of 10p each, representing a 14.60% holding of Acambis' issued share capital.

Of these 15,724,759 shares:

- a) The interest in 13,942,544 shares arose from a beneficial interest held by Goldman Sachs International, a wholly-owned indirect subsidiary of GS Inc. These shares are, or will be, registered at CREST in account CREPTIME; and
- b) The interest in 1,421,715 shares arose from an interest held by Goldman, Sachs & Co., a wholly-owned direct subsidiary of GS Inc, acting as custodian for its customers. These shares are, or will be, registered in the name of Goldman Sachs Securities (Nominees), Limited; and
- c) The interest in 360,500 shares arose from an interest held by GS&Co, acting as custodian of 180,250 ADRs; these ADRs are, or will be, held at The Depositary Trust Company, New York.

-ends-

Enquiries:

Acambis plc

Elizabeth Brown, Company Secretary: Tel: +44 (0) 1223 275 300
Lyndsay Wright, VP, Communications and Investor Relations: Tel: +44 (0) 1223 275 300

Edgar Filing: ACAMBIS PLC - Form 6-K

About Acambis

Acambis is a leading biotechnology company targeting infectious diseases with novel vaccines. Acambis' development-stage pipeline includes vaccines that could either offer improvements over existing products or target unmet medical needs. As well as ChimeriVax-JE, Acambis' proprietary ChimeriVax technology, developed in association with St Louis University, has also been used to develop ChimeriVax-West Nile, which is undergoing Phase 2 clinical testing, making it the most advanced investigational vaccine against the West Nile virus. Acambis also has the only vaccine in development against Clostridium difficile bacteria, a leading cause of hospital-acquired infections. Recognised internationally as the leading producer of smallpox vaccines, Acambis is developing an investigational smallpox vaccine, ACAM2000, and is manufacturing emergency-use stockpiles of this investigational vaccine for the US Government and other governments around the world.

Acambis is based in Cambridge, UK and Cambridge, Massachusetts, US, and is listed on the London Stock Exchange (ACM). More information is available at www.acambis.com.

"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995:

The statements in this news release that are not historical facts are forward-looking statements that involve risks and uncertainties, including the timing and results of clinical trials, product development, manufacturing and commercialisation risks, the risks of satisfying the regulatory approval process in a timely manner, the need for and the availability of additional capital. For a discussion of these and other risks and uncertainties see "Risk management" in the Company's 2005 Annual Report and "Risk factors" in its Form 20-F, in addition to those detailed on the Company's website and in the Company's filings made with the Securities and Exchange Commission from time to time. These forward-looking statements are based on estimates and assumptions made by the management of Acambis and are believed to be reasonable, though are inherently uncertain and difficult to predict. Actual results or experience could differ materially from the forward-looking statements.

Enclosure 4

Holding in Company

Cambridge, UK and Cambridge, Massachusetts - 16 February 2007 - Acambis plc ("Acambis") (LSE: ACM) announces an interest in its shares by The Goldman Sachs Group, Inc.

On 15 February 2007, Acambis received notification that, as of the close of business on 13 February 2007, The Goldman Sachs Group, Inc., ("GS Inc") of 85 Broad Street, New York, NY 10004, USA, was interested in a total of 15,004,902 ordinary shares of 10p each, representing a 13.94% holding of Acambis' issued

Edgar Filing: ACAMBIS PLC - Form 6-K

share capital.

Of these 15,004,902 shares:

a) The interest in 1,421,715 shares arose from an interest held by Goldman, Sachs & Co., a wholly-owned direct subsidiary of GS Inc, acting as custodian for its customers. These shares are, or will be, registered in the name of Goldman Sachs Securities (Nominees), Limited; and

b) The interest in 13,232,687 shares arose from a beneficial interest held by Goldman Sachs International, a wholly-owned indirect subsidiary of GS Inc. These shares are, or will be, registered at CREST in account CREPTMP; and

c) The interest in 350,500 shares arose from an interest held by GS&Co, acting as custodian of 175,250 ADRs; these ADRs are, or will be, held at The Depositary Trust Company, New York.

-ends-

Enquiries:

Acambis plc

Elizabeth Brown, Company Secretary: Tel: +44 (0) 1223 275 300

Lyndsay Wright, VP, Communications and Investor Relations: Tel: +44 (0) 1223 275 300

About Acambis

Acambis is a leading biotechnology company targeting infectious diseases with novel vaccines. Acambis' development-stage pipeline includes vaccines that could either offer improvements over existing products or target unmet medical needs. As well as ChimeriVax-JE, Acambis' proprietary ChimeriVax technology, developed in association with St Louis University, has also been used to develop ChimeriVax-West Nile, which is undergoing Phase 2 clinical testing, making it the most advanced investigational vaccine against the West Nile virus. Acambis also has the only vaccine in development against *Clostridium difficile* bacteria, a leading cause of hospital-acquired infections. Recognised internationally as the leading producer of smallpox vaccines, Acambis is developing an investigational smallpox vaccine, ACAM2000, and is manufacturing emergency-use stockpiles of this investigational vaccine for the US Government and other governments around the world.

Acambis is based in Cambridge, UK and Cambridge, Massachusetts, US, and is listed on the London Stock Exchange (ACM). More information is available at www.acambis.com.

"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995:

The statements in this news release that are not historical facts are forward-looking statements that involve risks and uncertainties, including the timing and results of clinical trials, product development, manufacturing and commercialisation risks, the risks of satisfying the regulatory approval process in a timely manner, the need for and the availability of additional capital. For a discussion of these and other risks and uncertainties see "Risk management" in the Company's 2005 Annual Report and "Risk factors" in its Form 20-F, in addition to those detailed on the Company's website and in the Company's filings made with the Securities and Exchange Commission from time to time. These forward-looking statements are based on estimates and assumptions made by the

Edgar Filing: ACAMBIS PLC - Form 6-K

management of Acambis and are believed to be reasonable, though are inherently uncertain and difficult to predict. Actual results or experience could differ materially from the forward-looking statements.

Enclosure 5

Holding in Company

Cambridge, UK and Cambridge, Massachusetts - 19 February 2007 - Acambis plc ("Acambis") (LSE: ACM) announces an interest in its shares by The Goldman Sachs Group, Inc.

On 16 February 2007, Acambis received notification that, as of the close of business on 14 February 2007, The Goldman Sachs Group, Inc., ("GS Inc") of 85 Broad Street, New York, NY 10004, USA, was interested in a total of 12,900,149 ordinary shares of 10p each, representing a 11.98% holding of Acambis' issued share capital.

Of these 12,900,149 shares:

- a) The interest in 1,421,715 shares arose from an interest held by Goldman, Sachs & Co., a wholly-owned direct subsidiary of GS Inc, acting as custodian for its customers. These shares are, or will be, registered in the name of Goldman Sachs Securities (Nominees), Limited; and
- b) The interest in 11,127,934 shares arose from a beneficial interest held by Goldman Sachs International, a wholly-owned indirect subsidiary of GS Inc. These shares are, or will be, registered at CREST in account CREPTMP; and
- c) The interest in 350,500 shares arose from an interest held by GS&Co, acting as custodian of 175,250 ADRs; these ADRs are, or will be, held at The Depositary Trust Company, New York.

-ends-

Enquiries:

Acambis plc

Elizabeth Brown, Company Secretary: Tel: +44 (0) 1223 275 300

Lyndsay Wright, VP, Communications and Investor Relations: Tel: +44 (0) 1223 275 300

About Acambis

Acambis is a leading biotechnology company targeting infectious diseases with novel vaccines. Acambis' development-stage pipeline includes vaccines that could

Edgar Filing: ACAMBIS PLC - Form 6-K

either offer improvements over existing products or target unmet medical needs. As well as ChimeriVax-JE, Acambis' proprietary ChimeriVax technology, developed in association with St Louis University, has also been used to develop ChimeriVax-West Nile, which is undergoing Phase 2 clinical testing, making it the most advanced investigational vaccine against the West Nile virus. Acambis also has the only vaccine in development against Clostridium difficile bacteria, a leading cause of hospital-acquired infections. Recognised internationally as the leading producer of smallpox vaccines, Acambis is developing an investigational smallpox vaccine, ACAM2000, and is manufacturing emergency-use stockpiles of this investigational vaccine for the US Government and other governments around the world.

Acambis is based in Cambridge, UK and Cambridge, Massachusetts, US, and is listed on the London Stock Exchange (ACM). More information is available at www.acambis.com.

"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995:

The statements in this news release that are not historical facts are forward-looking statements that involve risks and uncertainties, including the timing and results of clinical trials, product development, manufacturing and commercialisation risks, the risks of satisfying the regulatory approval process in a timely manner, the need for and the availability of additional capital. For a discussion of these and other risks and uncertainties see "Risk management" in the Company's 2005 Annual Report and "Risk factors" in its Form 20-F, in addition to those detailed on the Company's website and in the Company's filings made with the Securities and Exchange Commission from time to time. These forward-looking statements are based on estimates and assumptions made by the management of Acambis and are believed to be reasonable, though are inherently uncertain and difficult to predict. Actual results or experience could differ materially from the forward-looking statements.

Enclosure 6

Holding in Company

Cambridge, UK and Cambridge, Massachusetts - 23 February 2007 - Acambis plc ("Acambis") (LSE: ACM) announces an interest in its shares by The Goldman Sachs Group, Inc.

On 23 February 2007, Acambis received notification that, as of the close of business on 21 February 2007, The Goldman Sachs Group, Inc., ("GS Inc") of 85 Broad Street, New York, NY 10004, USA, was interested in a total of 13,069,809 ordinary shares of 10p each, representing a 12.04% holding of Acambis' issued share capital.

Of these 13,069,809 shares:

- a) The interest in 1,421,715 shares arose from an interest held by Goldman, Sachs & Co., a wholly-owned direct subsidiary of GS Inc, acting as custodian for its customers. These shares are, or will be, registered in the name of Goldman Sachs Securities (Nominees), Limited; and
- b) The interest in 11,297,594 shares arose from a beneficial interest held by

Edgar Filing: ACAMBIS PLC - Form 6-K

Goldman Sachs International, a wholly-owned indirect subsidiary of GS Inc. These shares are, or will be, registered at CREST in account CREPTMP; and

c) The interest in 350,500 shares arose from an interest held by GS&Co, acting as custodian of 175,250 ADRs; these ADRs are, or will be, held at The Depositary Trust Company, New York.

-ends-

Enquiries:

Acambis plc

Elizabeth Brown, Company Secretary:

Tel: +44 (0) 1223 275 300

Lyndsay Wright, VP, Communications and Investor Relations:

Tel: +44 (0) 1223 275 300

About Acambis

Acambis is a leading biotechnology company targeting infectious diseases with novel vaccines. Acambis' development-stage pipeline includes vaccines that could either offer improvements over existing products or target unmet medical needs. As well as ChimeriVax-JE, Acambis' proprietary ChimeriVax technology, developed in association with St Louis University, has also been used to develop ChimeriVax-West Nile, which is undergoing Phase 2 clinical testing, making it the most advanced investigational vaccine against the West Nile virus. Acambis also has the only vaccine in development against Clostridium difficile bacteria, a leading cause of hospital-acquired infections. Recognised internationally as the leading producer of smallpox vaccines, Acambis is developing an investigational smallpox vaccine, ACAM2000, and is manufacturing emergency-use stockpiles of this investigational vaccine for the US Government and other governments around the world.

Acambis is based in Cambridge, UK and Cambridge, Massachusetts, US, and is listed on the London Stock Exchange (ACM). More information is available at www.acambis.com.

"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: The statements in this news release that are not historical facts are forward-looking statements that involve risks and uncertainties, including the timing and results of clinical trials, product development, manufacturing and commercialisation risks, the risks of satisfying the regulatory approval process in a timely manner, the need for and the availability of additional capital. For a discussion of these and other risks and uncertainties see "Risk management" in the Company's 2005 Annual Report and "Risk factors" in its Form 20-F, in addition to those detailed on the Company's website and in the Company's filings made with the Securities and Exchange Commission from time to time. These forward-looking statements are based on estimates and assumptions made by the management of Acambis and are believed to be reasonable, though are inherently uncertain and difficult to predict. Actual results or experience could differ materially from the forward-looking statements.

Enclosure 7

Edgar Filing: ACAMBIS PLC - Form 6-K

Notice of results

Cambridge, UK and Cambridge, Massachusetts - 28 February 2007 - Acambis plc ("Acambis") (LSE: ACM) will announce its preliminary results for the year ended 31 December 2006 on Thursday, 15 March 2007.

The results announcement will be released at 7.00am GMT. A meeting and a conference call for analysts will be held at 9.00am GMT.

An instant replay of the conference call will be available from 11.00am on Thursday, 15 March until 11.00am on Thursday, 22 March 2007. The UK dial-in number for this replay is +44 (0) 20 8196 1998 and the US dial in number is 001 866 583 1035. The pin code is 949716.

A webcast of the call will also be available via Acambis' website at www.acambis.com. The webcast replay will be available for 12 months until 15 March 2008.

-ends-

Enquiries:

Acambis plc
Lyndsay Wright, VP, Communications and Investor Relations
Tel: +44 (0) 1223 275 300

Brunswick
Gill Tempest
Tel: +44 (0) 20 7404 5959

About Acambis

Acambis is a leading biotechnology company targeting infectious diseases with novel vaccines. Acambis' development-stage pipeline includes vaccines that could either offer improvements over existing products or target unmet medical needs. As well as ChimeriVax-JE, Acambis' proprietary ChimeriVax technology, developed in association with St Louis University, has also been used to develop ChimeriVax-West Nile, which is undergoing Phase 2 clinical testing, making it the most advanced investigational vaccine against the West Nile virus. Acambis also has the only vaccine in development against *Clostridium difficile* bacteria, a leading cause of hospital-acquired infections. Recognised internationally as the leading producer of smallpox vaccines, Acambis is developing an investigational smallpox vaccine, ACAM2000, and is manufacturing emergency-use stockpiles of this investigational vaccine for the US Government and other governments around the world.

Acambis is based in Cambridge, UK and Cambridge, Massachusetts, US, and is listed on the London Stock Exchange (ACM). More information is available at www.acambis.com.

"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995:

The statements in this news release that are not historical facts are forward-looking statements that involve risks and uncertainties, including the timing and results of clinical trials, product development, manufacturing and commercialisation risks, the risks of satisfying the regulatory approval process in a timely manner, the need for and the availability of additional capital. For a discussion of these and other risks and uncertainties see "Risk management" in the Company's 2005 Annual Report and "Risk factors" in its Form 20-F, in

Edgar Filing: ACAMBIS PLC - Form 6-K

addition to those detailed on the Company's website and in the Company's filings made with the Securities and Exchange Commission from time to time. These forward-looking statements are based on estimates and assumptions made by the management of Acambis and are believed to be reasonable, though are inherently uncertain and difficult to predict. Actual results or experience could differ materially from the forward-looking statements.

Enclosure 8

Acambis' JE vaccine meets and exceeds primary endpoint in pivotal Phase 3 efficacy trial

Cambridge, UK and Cambridge, Massachusetts - 1 March 2007 - Acambis plc (Acambis) (LSE: ACM) announces that its investigational single-dose vaccine against Japanese encephalitis (JE), ChimeriVax™-JE, has met and exceeded the primary immunogenicity endpoint in a pivotal Phase 3 efficacy trial.

In the randomised, double-blind, multi-centre Phase 3 study, 820 adult subjects were vaccinated at a 1:1 ratio with either Acambis' single-dose ChimeriVax-JE or JE-VAX(R), the licensed three-dose JE vaccine. The trial was designed to compare the immunogenicity 30 days after immunisation with a single dose of ChimeriVax-JE or with three doses of JE-VAX. The subjects received either two doses of placebo (saline) followed by one dose of ChimeriVax-JE or the full three-dose schedule of JE-VAX.

The primary efficacy endpoint, seroconversion rates based on neutralising antibodies against the relevant homologous JE virus, was met, demonstrating the non-inferiority of ChimeriVax-JE to JE-VAX. Of the subjects vaccinated with ChimeriVax-JE, 99.1% of subjects seroconverted compared with 74.8% of subjects in the JE-VAX group. The efficacy of ChimeriVax-JE was also shown to be statistically superior to JE-VAX (p